RT Journal Article
SR Electronic
T1 The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1441
OP 1441
VO 56
IS supplement 3
A1 yang, Jigang
YR 2015
UL http://jnm.snmjournals.org/content/56/supplement_3/1441.abstract
AB 1441 Objectives Anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (anti-3-18F-FACBC) PET/CT has been used for detecting prostate carcinoma relapse. The aim of this study was to systematically review and perform a meta-analysis of published data regarding the performance of 18F-FACBC PET/CT in the diagnosis of recurrent prostate carcinoma.Methods A comprehensive review of the literature regarding the role of 18F-FACBC PET/CT in the diagnosis of recurrent prostate carcinoma. Pooled sensitivity, specificity and the area under the receiver-operating characteristic of 18F-FACBC PET/CT in the diagnosis of recurrent prostate carcinoma were calculated based on these inclusive study.Results Six studies comprising 251 patients, suspicious of prostate carcinoma recurrence, were included into this meta-analysis. 18F-FACBC PET/CT had a 87% pooled sensitivity, 66% pooled specificity, 0.93 the area under the receiver-operating characteristic curve on a per patient-based analysis in detecting prostate carcinoma recurrence.Conclusions 18F-FACBC PET/CT was an accurate, noninvasive, metabolic imaging technique in the diagnosis of prostate carcinoma relapse. 18F-FACBC PET/CT is an upcoming diagnostic modality in the diagnosis of prostate carcinoma relapse.